FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892029016> ?p ?o ?g. }

• W2892029016 abstract "11028 Background: HDMTX followed by leucovorin rescue is well established as part of MAP chemotherapy for osteosarcoma. However, leucovorin rescue is not always effective as rescue, resulting in delays to subsequent courses of chemotherapy. Methods: This retrospective observational study involved patients ≥2 years of age with osteosarcoma treated with MAP during 2009 - 2014. Data was extracted from medical records from five clinics in Poland, Hungary, Norway and Sweden. The study objective was to determine to what extent patients treated with MAP encountered treatment delays due to MTX-related toxicity or delayed MTX elimination. Results: All patients fulfilling the inclusion criteria were included. Of 116 patients (ages 5-39 with a mean of 14 years; 59% males), 97% completed their first MAP cycle while only 48% completed six treatment cycles. The analysis of the primary endpoint included 114 evaluable patients. At least one treatment delay due to MTX toxicity or delayed MTX elimination was reported for 89 patients (78%) and only six patients (5%) completed the entire MAP treatment according to plan. Delay in subsequent treatment was observed following 183 of 369 evaluated MAP cycles (50%). About three quarters of the delays were found to be due to MTX-related toxicity while only a small number were related to delayed MTX elimination. The treatment related issues most commonly registered were increased liver enzymes, hematological disturbances, increased bilirubin and mucositis. Conclusions: We found at least one treatment delay due to MTX toxicity or delayed MTX elimination in 78% of all MAP-treated patients and that 50% of the administered MAP cycles resulted in a delay in subsequent treatment, mostly due to MTX toxicity. Only six patients (5%) completed the entire MAP treatment according to plan. The retrospective methodology with broad inclusion criteria implies that the results can be extrapolated to the entire target population. Thus, there appears to be an unmet need for a more effective HDMTX rescue that could reduce MTX toxicity and be expected to enable more patients to maintain planned MAP treatment intensity and duration, thereby improving the overall efficacy of the MAP regimen." @default.
• W2892029016 created "2018-09-27" @default.
• W2892029016 creator A5022457834 @default.
• W2892029016 creator A5026709868 @default.
• W2892029016 creator A5031377846 @default.
• W2892029016 creator A5037999437 @default.
• W2892029016 creator A5048329276 @default.
• W2892029016 creator A5058806380 @default.
• W2892029016 creator A5079719371 @default.
• W2892029016 creator A5090145105 @default.
• W2892029016 date "2017-05-20" @default.
• W2892029016 modified "2023-10-18" @default.
• W2892029016 title "Failure rate of standard rescue with leucovorin for high-dose methotrexate (HDMTX) in osteosarcoma." @default.
• W2892029016 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.11028" @default.
• W2892029016 hasPublicationYear "2017" @default.
• W2892029016 type Work @default.
• W2892029016 sameAs 2892029016 @default.
• W2892029016 citedByCount "0" @default.
• W2892029016 crossrefType "journal-article" @default.
• W2892029016 hasAuthorship W2892029016A5022457834 @default.
• W2892029016 hasAuthorship W2892029016A5026709868 @default.
• W2892029016 hasAuthorship W2892029016A5031377846 @default.
• W2892029016 hasAuthorship W2892029016A5037999437 @default.
• W2892029016 hasAuthorship W2892029016A5048329276 @default.
• W2892029016 hasAuthorship W2892029016A5058806380 @default.
• W2892029016 hasAuthorship W2892029016A5079719371 @default.
• W2892029016 hasAuthorship W2892029016A5090145105 @default.
• W2892029016 hasConcept C126322002 @default.
• W2892029016 hasConcept C143998085 @default.
• W2892029016 hasConcept C2777760704 @default.
• W2892029016 hasConcept C2781059491 @default.
• W2892029016 hasConcept C502942594 @default.
• W2892029016 hasConcept C71924100 @default.
• W2892029016 hasConceptScore W2892029016C126322002 @default.
• W2892029016 hasConceptScore W2892029016C143998085 @default.
• W2892029016 hasConceptScore W2892029016C2777760704 @default.
• W2892029016 hasConceptScore W2892029016C2781059491 @default.
• W2892029016 hasConceptScore W2892029016C502942594 @default.
• W2892029016 hasConceptScore W2892029016C71924100 @default.
• W2892029016 hasLocation W28920290161 @default.
• W2892029016 hasOpenAccess W2892029016 @default.
• W2892029016 hasPrimaryLocation W28920290161 @default.
• W2892029016 hasRelatedWork W128114226 @default.
• W2892029016 hasRelatedWork W1965145581 @default.
• W2892029016 hasRelatedWork W1974031166 @default.
• W2892029016 hasRelatedWork W2012030246 @default.
• W2892029016 hasRelatedWork W2090134120 @default.
• W2892029016 hasRelatedWork W2154279679 @default.
• W2892029016 hasRelatedWork W2260916734 @default.
• W2892029016 hasRelatedWork W2277319397 @default.
• W2892029016 hasRelatedWork W2402824420 @default.
• W2892029016 hasRelatedWork W2406085252 @default.
• W2892029016 hasRelatedWork W2409081275 @default.
• W2892029016 hasRelatedWork W2412680536 @default.
• W2892029016 hasRelatedWork W2415649223 @default.
• W2892029016 hasRelatedWork W2415925101 @default.
• W2892029016 hasRelatedWork W2762756232 @default.
• W2892029016 hasRelatedWork W3017329466 @default.
• W2892029016 hasRelatedWork W3030361853 @default.
• W2892029016 hasRelatedWork W2182842972 @default.
• W2892029016 hasRelatedWork W2676029483 @default.
• W2892029016 hasRelatedWork W59713603 @default.
• W2892029016 isParatext "false" @default.
• W2892029016 isRetracted "false" @default.
• W2892029016 magId "2892029016" @default.
• W2892029016 workType "article" @default.